Table 1.
Pharmacokinetics of PDE5 inhibitors (from Hatzimouratidis et al., 2016)
| PDE5 inhibitor | Tmax (h) | t 1/2 (h) | Cmax (ng·mL−1) | AUC (ng × h·mL−1) |
|---|---|---|---|---|
| Avanafil 200 mg | 0.75 | 5.1 | 2920 | 8490 |
| Lodenafil 160 mg | 1.2 | 2.4 | 157 | 530 |
| Mirodenafil 100 mg | 1.4 | 2.5 | 2989 | 7907 |
| Sildenafil 100 mg | 0.95 | 3.98 | 514 | 1670 |
| Tadalafil 20 mg | 2 | 17.5 | 378 | 8066 |
| Vardenafil FCT 20 mg | 0.66 | 3.9 | 20.9 | 74.5 |
| Vardenafil ODT 10 mg | 1.5 | 4.23 | 7.34 | 30.39 |
| Udenafil 200 mg | 0.76 | 9.88 | 1137 | 7898 |
AUC, area under the curve; Cmax, maximum plasma concentration; FCT, film‐coated tablet;
ODT, oro‐dispersible tablet; PDE5, phosphodiesterase type 5; t 1/2, time required for elimination of one half of the inhibitor from plasma; Tmax, time required for attaining maximum plasma concentration.
PK data were obtained after single‐dose oral administration of the different PDE5 inhibitors.